Drugs / Allogeneic Mesenchymal Stem Cells
Allogeneic Mesenchymal Stem Cells
also known as
AlloMSC · alloBM-MSCs · aMBMC · Bone Marrow Derived Allogeneic Mesenchymal Stem Cells · mesenchymal stromal cells · MSC · MSCs · Stempeucel - CLI
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT02213705 | May 2014 → Feb 2020 | systemic sclerosis | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 1/2 | NCT00962923 | Aug 2009 → Dec 2010 | systemic sclerosis | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT00953485 | Jun 2009 → Dec 2010 | Sjogren syndrome | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT02104440 | Oct 2013 → Mar 2017 | — | Red de Terapia Celular | Completed | No outcome recorded |
| Phase 2 | NCT01770613 | Feb 2013 → May 2016 | ST-elevation myocardial infarction | Stemedica Cell Technologies, Inc. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT01591200 | Jun 2012 → Apr 2016 | alcoholic liver cirrhosis | Stempeutics Research Pvt Ltd | Completed | No outcome recorded |
| Phase 2 | NCT01484574 | Jan 2012 → Feb 2014 | limb ischemia, thromboangiitis obliterans | Stempeutics Research Pvt Ltd | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01759212 | Oct 2012 → Jul 2022 | cardiomyopathy, heart failure | AHEPA University Hospital | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-09-13 | Stemedica Cell Technologies, Inc. | Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke stemedica.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Mesenchymal Stem Cells | “The aim of the study is to investigate safety and efficacy of intramyocardial implantation of allogeneic mesenchymal stem cells in patients with end-stage ischemic...” NCT01759212 ↗7“Allogeneic mesenchymal stem cells” NCT01770613 ↗ |
| Known as | alloBM-MSCs | “injection of a single dose of allogeneic bone marrow-MSCs (alloBM-MSCs) in patients with severe SSc (NCT02213705)” PMID 36928395 ↗ Apr 2023 |
| Known as | AlloMSC | “Allogeneic Mesenchymal Stem Cells (AlloMSC)” NCT00962923 ↗1“Allogeneic Mesenchymal Stem Cells (AlloMSC)” NCT00953485 ↗ |
| Known as | aMBMC | “human allogeneic mesenchymal bone marrow cells (aMBMC)” NCT01770613 ↗ |
| Known as | Bone Marrow Derived Allogeneic Mesenchymal Stem Cells | “High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery” NCT01591200 ↗ |
| Known as | mesenchymal stromal cells | “Mesenchymal stromal cells (MSCs) have recently emerged as an interesting therapeutic approach for patients with progressive systemic sclerosis (SSc), a rare and...” PMID 36928395 ↗ Apr 2023 |
| Known as | MSC | “allogeneic mesenchymal stem cells (MSC)” NCT02104440 ↗ |
| Known as | MSCs | “Mesenchymal stromal cells (MSCs) have recently emerged as an interesting therapeutic approach for patients with progressive systemic sclerosis (SSc), a rare and...” PMID 36928395 ↗ Apr 2023 |
| Known as | Stempeucel - CLI | “Intramuscular Administration of Stempeucel - CLI™ (ex Vivo Cultured Adult Bone Marrow Derived Allogeneic Mesenchymal Stem Cells)” NCT01484574 ↗ |
| Modality | Cell therapy | “allogeneic derived mesenchymal stem cell based therapy (MSCT)” NCT00953485 ↗ |
| Route | Intravenous | “will be infused intravenously” NCT00953485 ↗ |